# NCT03373877 (NCT03373877)

> Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03373877
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Samus Therapeutics, Inc.
- Conditions: Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions: PU-H71; Ruxolitinib
- Enrollment: 4
- Primary outcome: Incidence of adverse events
- Primary outcome: Maximum Tolerated Dose of PU-H71 (MTD)
- Primary outcome: Recommended Phase 2 Dose of PU-H71 (RP2D)
- Primary outcome: Pharmacokinetic profile of PU-H71: Area under the plasma concentration versus time curve (AUC)
- Primary outcome: Pharmacokinetic profile of PU-H71: Trough plasma concentration (Cmin)
- Primary outcome: Pharmacokinetic profile of PU-H71: Peak plasma concentration (Cmax)
- Primary outcome: Pharmacokinetic profile of PU-H71: Time to maximum plasma concentration (Tmax)
- Primary outcome: Pharmacokinetic profile of PU-H71: Plasma half-life (T1/2)

## Indexed commentary on NCT03373877 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03373877